InVivoSIM anti-human FGF‑23 (Burosumab Biosimilar)

Clone Catalog # Category
Burosumab SIM0079
USD 235 - USD 8140

About InVivoSIM anti-human FGF‑23 (Burosumab Biosimilar)

This biosimilar antibody uses the same variable regions as the therapeutic antibody Burosumab making it ideal for research use. Burosumab is a fully human IgG1 monoclonal antibody that specifically targets fibroblast growth factor 23 (FGF‑23). It binds circulating FGF‑23, blocking its interaction with the FGFR1–α‑Klotho receptor complex, thereby restoring phosphate homeostasis by enhancing renal phosphate reabsorption and increasing active vitamin D production. FGF‑23 is a hormone secreted by osteocytes and osteoblasts that regulates serum phosphate levels by inhibiting phosphate reabsorption in the kidney and suppressing vitamin D synthesis, ultimately reducing intestinal phosphate absorption. Clinically, Burosumab is approved for the treatment of X‑linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) in both adults and children. It has demonstrated significant improvements in serum phosphate, bone mineralization, rickets severity, and growth in XLH patients, with sustained efficacy and safety over extended use. This Burosumab biosimilar is well suited for studying phosphate and vitamin D metabolism, endocrine FGF signaling, bone biology, and therapeutic blockade of FGF‑23.

InVivoSIM anti-human FGF‑23 (Burosumab Biosimilar) Specifications

IsotypeHuman IgG1, κ
ImmunogenHuman FGF-23
Reported Applicationsin vivo functional assays in vitro functional assays Flow cytometry ELISA
FormulationPBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay
Aggregation<5% Determined by SEC
Purity>95% Determined by SDS-PAGE
Sterility0.2 μm filtration
ProductionPurified from cell culture supernatant in an animal-free facility
PurificationProtein A
Molecular Weight150 kDa
StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.